The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Open accessAbstract
Introduction: The purpose of this study was to compare urate-lowering (UL) efficacy and safety of daily febuxostat and allopurinol in subjects with gout and serum urate (sUA) ≥ 8.0 mg/dL in a six-month trial. Methods: Subjects (n = 2,269) were randomized to febuxostat 40 mg or 80 mg, or allopurinol 300 mg (200 mg in moderate renal impairment). Endpoints included the proportion of all subjects with sUA <6.0 mg/dL and the proportion of subjects with mild/moderate renal impairment and sUA <6.0 mg/dL. Safety assessments included blinded adjudication of each cardiovascular (CV) adverse event (AE) and death. Results: Comorbidities included: renal impairment (65%); obesity (64%); hyperlipidemia (42%); and hypertension (53%). In febuxostat 40 mg, febuxostat 80 mg, and allopurinol groups, primary endpoint was achieved in 45%, 67%, and 42%, respectively. Febuxostat 40 mg UL was statistically non-inferior to allopurinol, but febuxostat 80 mg was superior to both (P < 0.001). Achievement of target sUA in subjects with renal impairment was also superior with febuxostat 80 mg (72%; P < 0.001) compared with febuxostat 40 mg (50%) or allopurinol (42%), but febuxostat 40 mg showed greater efficacy than allopurinol (P = 0.021). Rates of AEs did not differ across treatment groups. Adjudicated (APTC) CV event rates were 0.0% for febuxostat 40 mg and 0.4% for both febuxostat 80 mg and allopurinol. One death occurred in each febuxostat group and three in the allopurinol group. Conclusions: Urate-lowering efficacy of febuxostat 80 mg exceeded that of febuxostat 40 mg and allopurinol (300/200 mg), which were comparable. In subjects with mild/moderate renal impairment, both febuxostat doses were more efficacious than allopurinol and equally safe. At the doses tested, safety of febuxostat and allopurinol was comparable. Clinical Trial Registration: NCT00430248
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A., Gabriel, S., Hirsch, R., Hochberg, M. C., Hunder, G. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23176 · Cited by 5,499
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
National Health and Nutrition Examination Survey
(2010) · Handbook of Disease Burdens and Quality of Life Measures · doi:10.1007/978-0-387-78665-0_6177 · Cited by 2,087
Serum Uric Acid and Cardiovascular Mortality: The NHANES I Epidemiologic Follow-up Study, 1971-1992
Fang, J., & Alderman, M. H. (2000) · JAMA · doi:10.1001/jama.283.18.2404 · Cited by 1,513
Preliminary criteria for the classification of the acute arthritis of primary gout
Wallace, S. L., Robinson, H., Masi, A. T., Decker, J. L., Mccarty, D. J., & Yü, T. (1977) · Arthritis & Rheumatism · doi:10.1002/art.1780200320 · Cited by 1,432
Zhang, W., Doherty, M., Bardin, T., Pascual, E., Barskova, V, Conaghan, P., Gerster, J., Jacobs, J., Leeb, B., Lioté, F., et al. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.055269 · Cited by 1,407
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
Self-citationSerum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study
Culleton, B. F., Larson, M. G., Kannel, W. B., & Levy, D. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-1-199907060-00003 · Cited by 1,282
Hande, K. R., Noone, R. M., & Stone, W. J. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90743-5 · Cited by 680
Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease
Choi, H. K., & Curhan, G. (2007) · Circulation · doi:10.1161/circulationaha.107.703389 · Cited by 666
Schumacher, H. R., Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., Lademacher, C., & Joseph‐Ridge, N. (2008) · Arthritis Care & Research · doi:10.1002/art.24209 · Cited by 638
Self-citationTerkeltaub, R. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp030733 · Cited by 456
Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout
Perez‐Ruiz, F., Calabozo, M., Pijoan, J. I., Herrero‐Beites, A. M., & Ruibal, A. (2002) · Arthritis Care & Research · doi:10.1002/art.10511 · Cited by 454
Shoji, A., Yamanaka, H., & Kamatani, N. (2004) · Arthritis Care & Research · doi:10.1002/art.20405 · Cited by 438
Wallace, K. L., Riedel, A. A., Joseph‐Ridge, N., & Wortmann, R. L. (2004) · PubMed · Cited by 426
Epidemiology of gout: is the incidence rising?
Arromdee, E., Michet, C. J., Crowson, C. S., O’Fallon, W. M., & Gabriel, S. E. (2002) · PubMed · Cited by 377
Gout and coronary heart disease: The framingham study
Abbott, R. D., Brand, F. N., Kannel, W. B., & Castelli, W. P. (1988) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(88)90127-8 · Cited by 355
Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us?
Baker, J. F., Krishnan, E., Chen, L., & Schumacher, H. R. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.03.043 · Cited by 354
Self-citationSelectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase
Takano, Y., Hase-Aoki, K., Horiuchi, H., Zhao, L., Kasahara, Y., Kondo, S., & Becker, M. A. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.031 · Cited by 334
Self-citationColchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.
Borstad, G. C., Bryant, L. R., Abel, M. P., Scroggie, D. A., Harris, M. D., & Alloway, J. A. (2004) · PubMed · Cited by 328
Long-term Cardiovascular Mortality Among Middle-aged Men With Gout
Krishnan, E. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.10.1104 · Cited by 328
Sarawate, C. A., Brewer, K. K., Yang, W., Patel, P. A., Schumacher, H. R., Saag, K. G., & Bakst, A. W. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.7.925 · Cited by 292
Self-citationBECKER, M. A., SCHUMACHER, H. R., MacDONALD, P. A., LLOYD, E., & LADEMACHER, C. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.080814 · Cited by 269
Self-citationBecker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Palo, W. A., Eustace, D., Vernillet, L., & Joseph‐Ridge, N. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20935 · Cited by 266
Self-citationPerez-Ruiz, F., Alonso-Ruiz, A., Calabozo, M., Herrero-Beites, A., García-Erauskin, G., & Ruiz-Lucea, E. (1998) · Annals of the Rheumatic Diseases · doi:10.1136/ard.57.9.545 · Cited by 257
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study
Schumacher, H. R., Becker, M. A., Lloyd, E., MacDonald, P. A., & Lademacher, C. (2008) · Rheumatology · doi:10.1093/rheumatology/ken457 · Cited by 251
Self-citationSynovial Fluid Analysis for Diagnosis of Intercritical Gout
Pascual, E., Batlle-Gualda, E., Martínez, A., Rosas, J., & Vela, P. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-10-199911160-00007 · Cited by 248
Dalbeth, N., Kumar, S., Stamp, L. K., & Gow, P. J. (2006) · PubMed · Cited by 226
Hyperuricemia, gout and the metabolic syndrome
Puig, J. G., & Martínez, M. A. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f4b1ed · Cited by 194
Ioachimescu, A. G., Brennan, D. M., Hoar, B. M., Hazen, S. L., & Hoogwerf, B. J. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23121 · Cited by 194
Li‐Yu, J., Clayburne, G. M., Sieck, M. S., Beutler, A. M., Rull, M., Eisner, E. V., & Schumacher, H. R. (2001) · PubMed · Cited by 193
Self-citationReinders, M. K., Haagsma, C., Jansen, T. L. T. A., van Roon, E. N., Delsing, J., van de Laar, M. A. F. J., & Brouwers, J. R. B. J. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091462 · Cited by 191
The changing epidemiology of gout
Roddy, E., Zhang, W., & Doherty, M. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0556 · Cited by 190
Quality of Life and Disability in Patients with Treatment-Failure Gout
BECKER, M. A., SCHUMACHER, H. R., BENJAMIN, K. L., GOREVIC, P., GREENWALD, M., FESSEL, J., EDWARDS, L., KAWATA, A. K., FRANK, L., WALTRIP, R., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.071229 · Cited by 187
Self-citationSerum Urate Levels and Gout Flares: Analysis From Managed Care Data
Sarawate, C. A., Patel, P. A., Schumacher, H. R., Yang, W., Brewer, K. K., & Bakst, A. W. (2006) · JCR: Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000209882.50228.9f · Cited by 186
Self-citationWhite, W. B., Faich, G., Borer, J. S., & Makuch, R. W. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00659-3 · Cited by 174
Hyperuricemia and Associated Diseases
Becker, M. A., & Jolly, M. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.02.005 · Cited by 162
Self-citationDalbeth, N., & Stamp, L. K. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00270.x · Cited by 153
Lowering serum uric acid levels: What is the optimal target for improving clinical outcomes in gout?
Pérez-Ruiz, F., & Lioté, F. (2007) · Arthritis Care & Research · doi:10.1002/art.23007 · Cited by 148
Perceptions of disease and health-related quality of life among patients with gout
Lee, S. J., Hirsch, J. D., Terkeltaub, R. A., Khanna, D., Singh, J. A., Sarkin, A. J., & Kavanaugh, A. (2008) · Rheumatology · doi:10.1093/rheumatology/kep047 · Cited by 138
Hak, A. E., & Choi, H. K. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f524a2 · Cited by 64
Treatment‐failure gout: A moving target
Edwards, N. L. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23803 · Cited by 57
We can make gout management more successful now
Becker, M. A., & Chohan, S. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f54d03 · Cited by 47
Self-citationEpidemiology of Crystal Arthropathy
Choi, H. K. (2006) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2006.03.002 · Cited by 35
Optimizing Therapy With Allopurinol: Factors Limiting Hypouricemic Efficacy
Chung, Y., STOCKER, S. L., Graham, G. G., & Day, R. O. (2008) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31815acb10 · Cited by 21
Cited by
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21772 · Cited by 1,536
Self-citationDalbeth, N., Merriman, T. R., & Stamp, L. K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00346-9 · Cited by 1,087
Khanna, D., Khanna, P. P., Fitzgerald, J. D., Singh, M. K., Bae, S., Neogi, T., Pillinger, M. H., Merill, J., Lee, S., Prakash, S., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21773 · Cited by 728
Self-citationDalbeth, N., Choi, H. K., Joosten, L. A. B., Khanna, P. P., Matsuo, H., Perez-Ruiz, F., & Stamp, L. K. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0115-y · Cited by 693
Metadata
- Authors
- Becker, M. A., Schumacher, H. R., Espinoza, L. R., Wells, A. F., MacDonald, P., Lloyd, E., & Lademacher, C.
- Venue
- Arthritis Research & Therapy
- Published
- 2010-04-06
- Volume
- 12
- Issue
- 2
- Pages
- R63-R63
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2106983312
- Cited by
- 529
- References
- 48
- FWCI
- 25.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.